CAMP4 Therapeutics (CAMP) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Pyxis Oncology (PYXS) over the past year, gaining 16.7% versus a loss of 21.2%. CAMP4 Therapeutics is the larger company by market cap ($241.0 million vs $240.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | PYXS |
|---|---|---|
| Share price | $3.84 | $2.01 |
| Market cap | $240.97M | $240.11M |
| 1-day change | -3.03% | -0.50% |
| YTD return | -37.36% | +74.78% |
| 1-year return | +16.72% | -21.18% |
| 5-year return | — | -82.92% |
| EPS (TTM) | $-2.32 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $5.55 |
| 52-week low | $2.86 | $1.03 |
| Distance from 52-week high | -50.45% | -63.78% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +175.26% | +331.34% |
| Average volume | 279.95K | 1.26M |
| Shares outstanding | 62.75M | 119.46M |
| Employees | 48 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed PYXS by 37.9 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
CAMP vs PYXS FAQ
Which is bigger, CAMP4 Therapeutics or Pyxis Oncology?
CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $240.97M compared with $240.11M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, CAMP or PYXS?
CAMP returned +16.72% over the past 12 months, compared with -21.18% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.